The Academy continues to recommend rotavirus immunization for most infants, despite data showing a rare association between the two vaccines licensed in the United States and excess cases of intussusception.

Approximately one in 20,000 to one in 100,000 infants given RotaTeq pentavalent rotavirus vaccine (RV5, Merck) or Rotarix monovalent rotavirus vaccine (RV1, GlaxoSmithKline) develop intussusception, according to surveillance data from the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Background rates of idiopathic intussusception approximate one in 3,000 U.S. infants. As a comparison of risk, approximately one in 4,500 infants are injured in car accidents annually.

The public health benefits and costs of vaccinating infants against rotavirus gastroenteritis were evaluated again while accounting for the rare association of RV1 and RV5 vaccines with intussusception. It remains clear that the benefits of rotavirus vaccines continue to far exceed the costs of their adverse effects (...

You do not currently have access to this content.